Similar articles

• [LEPROUS ERYTHEMA NODOSUM. ANALYTICAL STUDY AND PATHOGENIC ESSAY].

  ROLLIER R, ROLLIER M. ROLLIER R, et al. Ann Soc Belges Med Trop Parasitol Mycol. 1964;44:147-60. Ann Soc Belges Med Trop Parasitol Mycol. 1964. PMID: 14211535 French. No abstract available.
• Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum.

  Hastings RC, Trautman JR, Enna CD, Jacobson RR. Hastings RC, et al. Clin Pharmacol Ther. 1970 Jul-Aug;11(4):481-7. doi: 10.1002/cpt1970114481. Clin Pharmacol Ther. 1970. PMID: 4913866 Clinical Trial. No abstract available.
• Type II reaction without erythema nodosum leprosum masquerading as lymphoma.

  Mahajan R, Dogra S, Kaur I, Yadav S, Saikia UN, Budania A. Mahajan R, et al. Lepr Rev. 2012 Dec;83(4):378-83. Lepr Rev. 2012. PMID: 23614256
• Erythema nodosum leprosum: reactional leprosy.

  Cuevas J, Rodríguez-Peralto JL, Carrillo R, Contreras F. Cuevas J, et al. Semin Cutan Med Surg. 2007 Jun;26(2):126-30. doi: 10.1016/j.sder.2007.02.010. Semin Cutan Med Surg. 2007. PMID: 17544965 Review.
• Recognizing and managing the immunologic reactions in leprosy.

  Kamath S, Vaccaro SA, Rea TH, Ochoa MT. Kamath S, et al. J Am Acad Dermatol. 2014 Oct;71(4):795-803. doi: 10.1016/j.jaad.2014.03.034. Epub 2014 Apr 24. J Am Acad Dermatol. 2014. PMID: 24767732 Review.